Sven Mensing

Sven Mensing

AbbVie Inc - Chicago / United States
Others
AD Scientific Index ID: 4402007
-
person_outline Sven Mensing's MOST POPULAR ARTICLES
1-) Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopeniaA Kaefer, J Yang, P Noertersheuser, S Mensing, R Humerickhouse, ...Cancer chemotherapy and pharmacology 74 (3), 593-602, 20141022014
2-) Pharmacokinetics and exposure–efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'s disease: results from a randomized, multicenter, phase-3 …S Sharma, D Eckert, JS Hyams, S Mensing, RB Thakkar, AM Robinson, ...Inflammatory bowel diseases 21 (4), 783-792, 2015872015
3-) Impact of venetoclax exposure on clinical efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemiaKJ Freise, AK Jones, D Eckert, S Mensing, SL Wong, RA Humerickhouse, ...Clinical pharmacokinetics 56 (5), 515-523, 2017432017
4-) Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: an exposure‐response analysisS Agarwal, S Gopalakrishnan, S Mensing, J Potluri, J Hayslip, ...Hematological oncology 37 (4), 464-473, 2019412019
5-) Methods for treating HCVBM Bernstein, RM Menon, A Khatri, S Mensing, S Dutta, DE Cohen, ...US Patent 8,809,265, 2014372014